Pegaptanib in the treatment of wet, age-related macular degeneration.

Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm (2009) 1.65

Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12

Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) (2013) 0.86

The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol (2010) 0.81

Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside. Int J Nanomedicine (2016) 0.78

Chemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect. Bioorg Med Chem (2014) 0.78

Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. Biol Ther (2012) 0.77

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size. Clin Ophthalmol (2012) 0.76

Aptamers in Therapeutics. J Clin Diagn Res (2016) 0.75

Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration. MAbs (2016) 0.75

Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes. Biomedicines (2017) 0.75

The biology of VEGF and its receptors. Nat Med (2003) 32.13

Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol (2004) 13.78

Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01

Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol (1984) 4.68

Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci (1996) 3.21

Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17

2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem (1998) 3.03

Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci (1996) 2.87

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology (2003) 2.47

Histopathology of age-related macular degeneration. Mol Vis (1999) 2.27

VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci (2003) 2.09

Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol (1997) 1.65

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 1.62

Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol (2001) 1.53

Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci (1994) 1.52

Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol (2004) 1.50

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A (2005) 1.48

Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol (1997) 1.44

Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol (1996) 1.35

Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl (1999) 1.29

Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol (2006) 1.28

Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina (2005) 1.23

Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res (2000) 1.14

neovascular age-related macular degeneration: Natural History and Treatment Outcomes. Retina (2005) 1.09

Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci (2003) 1.03

Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim (1999) 1.00

Pegaptanib: in exudative age-related macular degeneration. Drugs (2005) 0.96

Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother (2005) 0.92

Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging (2006) 0.92

Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther (2003) 0.88

Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol (2006) 0.86